3.72
price down icon3.12%   -0.12
after-market アフターアワーズ: 3.74 0.02 +0.54%
loading
前日終値:
$3.84
開ける:
$3.85
24時間の取引高:
1.49M
Relative Volume:
0.68
時価総額:
$247.88M
収益:
$80.00M
当期純損益:
$-76.12M
株価収益率:
-3.2447
EPS:
-1.1465
ネットキャッシュフロー:
$-63.88M
1週間 パフォーマンス:
-0.27%
1か月 パフォーマンス:
+0.81%
6か月 パフォーマンス:
-62.76%
1年 パフォーマンス:
-46.24%
1日の値動き範囲:
Value
$3.66
$3.90
1週間の範囲:
Value
$3.61
$3.915
52週間の値動き範囲:
Value
$2.83
$15.74

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
名前
Fulcrum Therapeutics Inc
Name
セクター
Healthcare (1100)
Name
電話
617-651-8851
Name
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
職員
55
Name
Twitter
@fulcrumtx
Name
次回の収益日
2026-08-04
Name
最新のSEC提出書
Name
FULC's Discussions on Twitter

Compare FULC vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
FULC icon
FULC
Fulcrum Therapeutics Inc
3.72 243.88M 80.00M -76.12M -63.88M -1.1465
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
529.59 126.07B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
649.81 65.37B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
916.80 57.70B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
313.04 40.19B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
189.99 39.82B 742.00K -1.37B -1.07B -7.0731

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-12 開始されました JP Morgan Overweight
2025-11-24 開始されました Truist Buy
2025-07-29 アップグレード H.C. Wainwright Neutral → Buy
2025-05-23 アップグレード Leerink Partners Market Perform → Outperform
2025-05-15 アップグレード Cantor Fitzgerald Neutral → Overweight
2024-09-13 ダウングレード H.C. Wainwright Buy → Neutral
2024-09-12 ダウングレード BofA Securities Neutral → Underperform
2024-09-12 ダウングレード Cantor Fitzgerald Overweight → Neutral
2024-09-12 ダウングレード Leerink Partners Outperform → Market Perform
2024-09-12 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2024-09-12 ダウングレード Stifel Buy → Hold
2024-09-09 アップグレード BofA Securities Underperform → Neutral
2024-05-20 開始されました Cantor Fitzgerald Overweight
2024-03-13 開始されました RBC Capital Mkts Outperform
2023-09-25 開始されました Goldman Neutral
2023-08-23 アップグレード H.C. Wainwright Neutral → Buy
2023-08-22 アップグレード Stifel Hold → Buy
2023-05-04 ダウングレード Goldman Buy → Neutral
2023-03-10 ダウングレード Credit Suisse Outperform → Neutral
2023-03-10 ダウングレード H.C. Wainwright Buy → Neutral
2023-03-09 ダウングレード Stifel Buy → Hold
2023-02-28 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-02-24 ダウングレード BofA Securities Neutral → Underperform
2022-11-15 開始されました Goldman Buy
2022-03-08 開始されました Oppenheimer Outperform
2022-03-03 アップグレード BofA Securities Underperform → Neutral
2021-08-11 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-04-26 再開されました Credit Suisse Outperform
2021-03-22 開始されました Credit Suisse Outperform
2021-03-02 開始されました Stifel Buy
2020-10-16 開始されました Piper Sandler Overweight
2020-08-12 ダウングレード BofA Securities Neutral → Underperform
2020-08-12 繰り返されました H.C. Wainwright Buy
2020-08-12 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-06-19 ダウングレード BofA/Merrill Buy → Neutral
2020-06-17 開始されました BTIG Research Buy
2019-10-03 開始されました H.C. Wainwright Buy
2019-08-12 開始されました BofA/Merrill Buy
すべてを表示

Fulcrum Therapeutics Inc (FULC) 最新ニュース

pulisher
Jun 30, 2026

Insider Sell Alert: Alan Ezekowitz Sells 18,000 Shares of Fulcru - GuruFocus

Jun 30, 2026
pulisher
Jun 30, 2026

Fulcrum Therapeutics (FULC) director sells 18,000 shares under 10b5-1 plan - Stock Titan

Jun 30, 2026
pulisher
Jun 29, 2026

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

Price to sales forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026
pulisher
Jun 28, 2026

Price to book forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView

Jun 28, 2026
pulisher
Jun 27, 2026

Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit - Yahoo Finance

Jun 27, 2026
pulisher
Jun 26, 2026

[144] Fulcrum Therapeutics, Inc. SEC Filing - Stock Titan

Jun 26, 2026
pulisher
Jun 26, 2026

Fulcrum Therapeutics, Inc. Actuals & Estimates (NASDAQ:FULC) - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC) - Stock Titan

Jun 25, 2026
pulisher
Jun 25, 2026

EcoR1 Capital (FULC) reports shared control of 6.0M shares; 9.0% stake - Stock Titan

Jun 25, 2026
pulisher
Jun 25, 2026

Fulcrum Therapeutics Shareholders Reaffirm Board and Governance Structure - TipRanks

Jun 25, 2026
pulisher
Jun 25, 2026

Fulcrum Therapeutics (FULC) details 2026 stockholder voting on directors and key proposals - Stock Titan

Jun 25, 2026
pulisher
Jun 25, 2026

Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey

Jun 25, 2026
pulisher
Jun 24, 2026

Fulcrum Therapeutics (FULC) Advances 1.8% as Shares Test Resistance Near $4.12Growth ETF - dars.gov.et

Jun 24, 2026
pulisher
Jun 24, 2026

Fulcrum Therapeutics Inc (FULC) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 24, 2026
pulisher
Jun 23, 2026

Fulcrum plunges after discontinuing lead program - MSN

Jun 23, 2026
pulisher
Jun 20, 2026

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securiti - The National Law Review

Jun 20, 2026
pulisher
Jun 19, 2026

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm - The National Law Review

Jun 19, 2026
pulisher
Jun 19, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - ACCESS Newswire

Jun 19, 2026
pulisher
Jun 19, 2026

2026-06-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out | NDAQ:FULC | Press Release - Stockhouse

Jun 19, 2026
pulisher
Jun 18, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jun 18, 2026
pulisher
Jun 18, 2026

Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations - NewMediaWire

Jun 18, 2026
pulisher
Jun 18, 2026

Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

Fulcrum Therapeutics Inc (FULC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations - NewMediaWire

Jun 17, 2026
pulisher
Jun 17, 2026

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 17, 2026
pulisher
Jun 17, 2026

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewir - The National Law Review

Jun 17, 2026
pulisher
Jun 17, 2026

Fulcrum Therapeutics Inc (FULC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Fulcrum Therapeutics Inc (FULC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026
pulisher
Jun 16, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 16, 2026
pulisher
Jun 15, 2026

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 15, 2026
pulisher
Jun 15, 2026

2026-06-15 | Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:FULC | Press Release - Stockhouse

Jun 15, 2026
pulisher
Jun 14, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect - ACCESS Newswire

Jun 14, 2026
pulisher
Jun 12, 2026

What's going on with Fulcrum Therapeutics stock on Thursday? - MSN

Jun 12, 2026
pulisher
Jun 12, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 12, 2026
pulisher
Jun 12, 2026

Fulcrum Therapeutics, Inc. Files Form 8-K Report with SEC – Company Information and Key Details (June 2026) - Minichart

Jun 12, 2026
pulisher
Jun 12, 2026

FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits

Jun 12, 2026
pulisher
Jun 11, 2026

Fulcrum Therapeutics Advances Restructuring with Leadership Changes - TipRanks

Jun 11, 2026
pulisher
Jun 11, 2026

Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart - Stock Titan

Jun 11, 2026
pulisher
Jun 11, 2026

Fulcrum Therapeutics, Inc. Announces Departure of Greg Tourangeau, Principal Accounting Officer - marketscreener.com

Jun 11, 2026
pulisher
Jun 11, 2026

A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs - Yahoo Finance

Jun 11, 2026
pulisher
Jun 11, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jun 11, 2026
pulisher
Jun 10, 2026

Tang entities report 5,451,800‑share stake in Fulcrum (FULC) - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

FULC stock crashes as cancer risk forces its only drug program's end - MSN

Jun 10, 2026

Fulcrum Therapeutics Inc (FULC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$111.54
price down icon 0.05%
$56.92
price down icon 1.47%
$35.39
price up icon 0.74%
ONC ONC
$309.46
price up icon 3.97%
$81.80
price up icon 2.56%
$189.99
price up icon 0.40%
大文字化:     |  ボリューム (24 時間):